Purpose: Data from two large phase III studies were analyzed to characterize the correlation
between the occurrence of rash during treatment with the epidermal growth factor receptor …

Rash is a class effect of HER1/epidermal growth factor receptor (EGFR)-targeted agents,
and has occurred with high frequency and in a dose-dependent manner in clinical trials of …

Rash and other cutaneous adverse events are class-effect toxicities seen with therapeutic
agents such as the small-molecule tyrosine kinase inhibitors erlotinib and gefitinib and …

Abstract Erlotinib (OSI-774; Tarceva™) is an orally available, highly specific epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. The results of 3 phase II studies with …

Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with
advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor …

Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR)
tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR …

BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

Skin toxicities are the most common side effects associated with the epidermal growth factor
receptor inhibitor erlotinib, occurring in most patients receiving the drug. Clinical trials …

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid
tumors, making it an attractive target for anticancer therapy. A number of agents that target …